Nelfinavir
- Generic Name
- Nelfinavir
- Brand Names
- Viracept
- Drug Type
- Small Molecule
- Chemical Formula
- C32H45N3O4S
- CAS Number
- 159989-64-7
- Unique Ingredient Identifier
- HO3OGH5D7I
- Background
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Stereotactic Body Radiation With Nelfinavir for Oligometastases
- Conditions
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2021-07-12
- Target Recruit Count
- 38
- Registration Number
- NCT01728779
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 33
- Registration Number
- NCT01555281
- Locations
- 🇨🇭
Kantonsspital Olten, Olten, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
🇮🇹Istituto Europeo di Oncologia IEO, Milano, Italy
Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
- Conditions
- Interventions
- Drug: NelfinavirDrug: CisplatinRadiation: Pelvic External Beam Radiation TherapyRadiation: BrachytherapyProcedure: Pharmacokinetic SamplingProcedure: Cervical BiopsyProcedure: Pelvic ExaminationProcedure: Pap SmearProcedure: AudiogramProcedure: ProctoscopyProcedure: CytoscopyProcedure: Renal UltrasoundProcedure: CT ScanProcedure: Whole Body PET/CT Scan
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 8
- Registration Number
- NCT01485731
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Radical Lung Radiotherapy Plus Nelfinavir
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Registration Number
- NCT01447589
- Locations
- 🇬🇧
Oxford Radcliffe NHS Trust, Oxford, Oxfordshire, United Kingdom
A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
- Conditions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT01445106
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01108666
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 7
- Registration Number
- NCT01086332
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 15
- Registration Number
- NCT01065844
- Locations
- 🇺🇸
The Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
- First Posted Date
- 2009-11-24
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT01020292
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 1
- Registration Number
- NCT00791336
- Locations
- 🇺🇸
The University of Iowa Department of Radiation Oncology, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.